AUS
NZ
UK
CA
USA
IND
Highlights
- Healthcare devices and corporate travel offered contrasting windows into the ASX mid-cap segment this week.
- Nanosonics and Corporate Travel Management show how mid-sized names can pair recurring revenue with cyclical recovery.
- Market participants are watching installed-base growth, travel demand and margins across the two companies.
Infection-prevention specialist Nanosonics (ASX:NAN), the maker of a widely used device that disinfects ultrasound probes in hospitals and clinics, drew attention across the ASX mid-cap segment this week as the healthcare sector showed signs of revival. The company sat alongside a very different mid-cap story in Corporate Travel Management (ASX:CTD), the global travel-management business that arranges and oversees business trips for large organisations. Together the pair illustrate the breadth of the mid-cap tier, spanning a healthcare name built on recurring consumable revenue and a services business geared to the ebb and flow of corporate activity.
Two windows into the mid-cap tier
The mid-cap segment is nothing if not diverse, and these two companies capture that range. One sells a medical device and the consumables that go with it, generating steady, repeatable revenue from an installed base of machines. The other manages corporate travel, a business that rises and falls with the confidence and activity of the organisations it serves. Between them they show how the middle tier houses both defensive and cyclical characteristics.
That diversity is part of the appeal. Because mid-cap names span so many industries, the segment offers exposure to a wide array of themes without the concentration that dominates the top of the market, where miners and banks loom large. For those building a rounded view of the market, the middle tier can fill gaps that the largest companies leave, which is part of why it has drawn renewed attention lately.
Nanosonics and the recurring model
Nanosonics has built its business around a device that disinfects ultrasound probes, addressing a genuine need in hospitals and clinics where infection control is paramount. The appeal of its model lies in the razor-and-blade structure: once a machine is installed, it requires a steady supply of consumables to operate, generating recurring revenue that accumulates as the installed base grows. That mix of hardware placement and ongoing consumables is a hallmark of a durable medical-device business.
The installed base is the engine of the story. Each device placed in a hospital represents a stream of future consumable sales, so growing the number of machines in use steadily enlarges the recurring revenue base. The company has worked to expand its footprint across major healthcare markets, and it continues to develop new products aimed at broadening its role in infection prevention beyond its original device.
The defensive nature of healthcare demand adds to the appeal. Infection control is not something hospitals can easily defer, which lends the consumables revenue a steadiness that many businesses lack. That resilience, paired with the scope to keep expanding its device footprint and product range, is why the company is treated as a quality mid-cap name rather than a speculative medical play.
Regulation is a quiet ally for this kind of business. Standards governing infection control in clinical settings tend to tighten over time, and equipment that helps facilities meet those requirements becomes harder to displace once adopted. That regulatory tailwind reinforces the stickiness of the installed base, since hospitals are reluctant to disrupt processes that keep them compliant and patients safe. It is one reason the recurring revenue is regarded as particularly durable.
Corporate Travel Management and the recovery
Corporate Travel Management occupies a more cyclical spot, arranging and managing business travel for companies and institutions around the world. Its role goes beyond booking flights, encompassing the technology, reporting and support that large organisations need to manage travel efficiently. That service-heavy model means the business earns fees tied to the volume and value of the travel it handles, which links its fortunes to corporate activity.
The business has been navigating the recovery in corporate travel, a market that was severely disrupted before rebuilding as organisations returned to face-to-face activity. As companies resumed travelling, demand for managed-travel services recovered, though the pace has varied across regions and industries. The trajectory of that recovery, and the company's success in winning new corporate accounts, sit at the centre of its story.
Technology is an increasingly important differentiator. Large clients value platforms that can manage complex itineraries, control costs and provide detailed reporting, and investment in these tools can help win and retain accounts. The company competes on the strength of its service and technology as much as on price, and its ability to keep clients loyal is a key measure of its progress in a competitive field.
Geographic spread shapes the story as well. Because the business operates across several regions, it is exposed to travel patterns that can recover at different speeds depending on local conditions and the mix of industries it serves. That spread can smooth the overall picture, since weakness in one market may be offset by strength in another, but it also means the pace of recovery is rarely uniform. Reading the trajectory therefore requires looking beneath the headline at how each region is faring.
Reading the mid-cap theme
Both companies sit within the mid-cap tier, the kind of names that can feature in the ASX 200 without dominating it. That positioning captures the balance the segment is known for: established enough to be substantial, yet retaining room to grow. Those wanting a wider view can explore the broader set of ASX Midcap Stocks spanning healthcare, services, consumer and financial names.
The contrast between the two is instructive. The healthcare name offers defensive, recurring revenue that grows steadily with its installed base, while the travel business offers exposure to a cyclical recovery that can accelerate as activity rebuilds. Holding both kinds of exposure is one way the mid-cap tier can balance steadiness against the upside of a rebound, which is a large part of its appeal.
It is also worth noting how mid-caps of this kind can be overlooked precisely because they sit between the two extremes of the market. They lack the household familiarity of the largest companies and the lottery-ticket allure of the smallest, which can leave them under-followed. For those willing to look, that relative neglect is part of what makes the segment interesting, since quality businesses can sometimes trade without the crowd that surrounds the market's biggest names.
Recurring versus cyclical revenue
The central distinction between the two stories is the nature of their revenue. Consumable sales tied to installed devices tend to be predictable and defensive, accumulating regardless of the economic weather. Travel-management fees, by contrast, swing with corporate confidence and activity. That difference shapes how each business behaves through the cycle and how the market assesses their prospects.
Risks worth keeping in view
Each company carries distinct hazards. The healthcare name must keep expanding its installed base and defending its position against competing infection-control approaches. The travel business is exposed to any renewed disruption to corporate activity, economic softness and intense competition. Market participants may weigh these uncertainties against the recurring revenue of one and the recovery runway of the other.
Where the mid-cap theme sits now
This week's contrasting stories underlined the breadth of the mid-cap segment. A defensive healthcare device maker and a cyclical travel-management business could hardly be more different, yet both belong to the same middle tier that has drawn renewed attention as the market weighs the outlook. That range is precisely what makes the segment interesting to those looking beyond the largest names.
Both stories also illustrate how mid-caps can offer a clearer view of a single theme than a sprawling large-cap conglomerate. One is a relatively focused bet on infection prevention, the other on the recovery and management of corporate travel. That focus can make the businesses easier to understand and to follow, since their fortunes hinge on a small number of identifiable drivers rather than a tangle of unrelated divisions. For those seeking targeted exposure, that clarity is part of the segment's charm.
As both companies move toward their next updates, attention is likely to settle on installed-base and consumables growth for the healthcare name and travel volumes and account wins for the services business. Those signals, more than any single session, will shape how the mid-cap theme is judged in the months ahead. For now, the two names have offered a reminder of the segment's diversity.
